Newsbenzinga
BioCryst Pharma Affirms FY2026 Sales Guidance of $635.000M-$660.000M vs $666.201M Est
· Published
Article summary
Please check the source for details.
An excerpt from the original article.Loading news article.
Please check the source for details.
An excerpt from the original article.
Comments —
Loading comments…